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Background
A phase I/II HIV vaccine trial among healthy volunteers
using a multiclade, multigene HIV-1 DNA prime/MVA
boost was conducted in Dar es Salaam, Tanzania.
Methods
Sixty HIV negative volunteers randomised to 3 groups of
20, received DNA plasmid vaccine at 1 mg intradermally
(i.d.) or 3.8 mg intramuscularly (i.m.) or placebo using
the Biojector. DNA plasmids (KI/SMI and Vecura) con-
taining HIV-1 gp160 subtypes A, B, C; rev B; p17/p24 gag
A, B and Rtmut B were given (n = 59) at months 0, 1 and
3. A single boost of 108 pfu of recombinant MVA express-
ing HIV-1 env, gag, pol of CRF01_AE (NIAID and WRAIR)
or placebo was administered i.m. (n = 50) at month 9.
Interferon (IFN)-gamma ELISpot responses were meas-
ured after stimulation with peptide pools representing
HIV-1 p17B, p24A, p55A, gp120A/B, gp120 B, gp41B,
gp160E and PolA. Criteria for positive ELISpot responses
were >55 spots/106 cells, >4 × background and >4 × base-
line.
Results
Two weeks after the DNA injections, 13/19(68%) i.d. and
9/19(47%) i.m. vaccinees responded to Gag. Two weeks
after the single MVA boost, all vaccine recipients
responded: 35 (100%) to Gag and 31(89%) to Env pep-
tide pools. The i.d. recipients reacted to more peptide
pools than i.m. recipients; p = 0.007. While there was no
significant difference between responders to the peptide
pool spanning the Gag protein, there was a higher
response to the Env gp160E peptide pool matching the
boost, i.d. vs i.m. responders; median 415 (n = 17) vs
median 187 (n = 12 ) p = 0.003.
Conclusion
Low dose, intradermal, multigene, multiclade HIV DNA
elicited higher and broader immune responses compared
to a higher dose given i.m. after a single boost with MVA
containing heterologous HIV genes. All these Tanzanian
vaccinees responded regardless of DNA priming route. In
addition, env immune responses to the matched heterol-
ogous boost were higher in the i.d. DNA recipients.
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